Dementia Update
description
Transcript of Dementia Update
![Page 1: Dementia Update](https://reader035.fdocuments.us/reader035/viewer/2022062408/56814462550346895db0f7fb/html5/thumbnails/1.jpg)
Dementia Update
October 1, 2013Dylan Wint, M.D.
Cleveland Clinic Lou Ruvo Center for Brain HealthLas Vegas, Nevada
![Page 2: Dementia Update](https://reader035.fdocuments.us/reader035/viewer/2022062408/56814462550346895db0f7fb/html5/thumbnails/2.jpg)
OutlineNew concepts in Alzheimer diseaseBiomarkers and in vivo diagnosisFuture trends in Alzheimer diseaseWhen it isn’t Alzheimer disease
Other common dementiasSigns of non-Alzheimer dementia
![Page 3: Dementia Update](https://reader035.fdocuments.us/reader035/viewer/2022062408/56814462550346895db0f7fb/html5/thumbnails/3.jpg)
Old Concepts
Traditional Diagnosis of ADCognitive disorder Insidious onset, gradual progression Interferes with activities/relationshipsNo other apparent cause
![Page 4: Dementia Update](https://reader035.fdocuments.us/reader035/viewer/2022062408/56814462550346895db0f7fb/html5/thumbnails/4.jpg)
Old Concepts
Consequences of traditionAD considered a diagnosis of exclusion
Patient, caregiver, provider uncertaintyConfusion with other diagnoses
Poor diagnostic specificity (max 85%)Limited progress
Symptom-driven trialsFailure of disease-modifying therapies
![Page 5: Dementia Update](https://reader035.fdocuments.us/reader035/viewer/2022062408/56814462550346895db0f7fb/html5/thumbnails/5.jpg)
Current Concepts
Goals of newer criteriaUtilize scientific advances, particularly
biomarkersDiagnose Alzheimer disease/dementia
earlier and more accuratelyEnable positive identification of Alzheimer
disease/dementiaClarify the relationship between Alzheimer
disease and Alzheimer dementia
![Page 6: Dementia Update](https://reader035.fdocuments.us/reader035/viewer/2022062408/56814462550346895db0f7fb/html5/thumbnails/6.jpg)
Current Concepts
Alzheimer disease (biological)Plaques (amyloid) and tangles (phos-tau)Cell death and cerebral atrophyDeterminative mutation
Alzheimer dementia (clinical)Overt manifestation of the diseaseFinal stage of Alzheimer disease
![Page 7: Dementia Update](https://reader035.fdocuments.us/reader035/viewer/2022062408/56814462550346895db0f7fb/html5/thumbnails/7.jpg)
Current ConceptsRisk factors > Protective factors
↓Pathological Alzheimer disease
↓Pathophysiological Alzheimer disease
↓Symptomatic Alzheimer disease
↓Alzheimer dementia
![Page 8: Dementia Update](https://reader035.fdocuments.us/reader035/viewer/2022062408/56814462550346895db0f7fb/html5/thumbnails/8.jpg)
Current Concepts It is possible to have Alzheimer disease
(biologically) without the typical signs of Alzheimer dementia
There may be syndromes that resemble Alzheimer dementia (clinically), but are not caused by Alzheimer disease
![Page 9: Dementia Update](https://reader035.fdocuments.us/reader035/viewer/2022062408/56814462550346895db0f7fb/html5/thumbnails/9.jpg)
Current ConceptsSome stage(s) of Alzheimer disease occur prior to dementia
Mild cognitive impairmentObjective cognitive (memory) declineGenerally preserved ADLsHigh risk of progression to dementia
Not all progressNot always Alzheimer disease
![Page 10: Dementia Update](https://reader035.fdocuments.us/reader035/viewer/2022062408/56814462550346895db0f7fb/html5/thumbnails/10.jpg)
Focus on Biomarkers
Why the emphasis on biomarkers?Detectable biological changes
Identify disease before clinical symptomsBetter chance of stopping disease
Related to underlying pathophysiologyIncrease specificityPotentially increase sensitivityDirect association with disease progression
![Page 11: Dementia Update](https://reader035.fdocuments.us/reader035/viewer/2022062408/56814462550346895db0f7fb/html5/thumbnails/11.jpg)
Biomarkers: FDG PET
Frontotemporal DementiaAlzheimer Disease
Hypometabolism
Frontal andanterior temporal
Parietal and temporal
Sensitivity 90-95%Specificity 60-75%
Coleman, Neuroimaging Clinic NA 2005Patwardhan et al, Radiology 2004
![Page 12: Dementia Update](https://reader035.fdocuments.us/reader035/viewer/2022062408/56814462550346895db0f7fb/html5/thumbnails/12.jpg)
Biomarker:Hippocampal Atrophy
NORMAL
ALZHEIMER
Hippocampus
Entorhinal
Perirhinal
• Mild generalized atrophy• No mesial temporal atrophy
• Moderate generalized atrophy• Mesial temporal atrophy• Sensitivity/specificity >85%• Detectable in early stages
Florida Alzheimer’s Disease Research Center
![Page 13: Dementia Update](https://reader035.fdocuments.us/reader035/viewer/2022062408/56814462550346895db0f7fb/html5/thumbnails/13.jpg)
Biomarkers: Cerebrospinal Fluid
Pho
spho
-tau
Beta-amyloid
444
195
↓ beta-amyloid
↑ phos-tau
Sensitivity 92%Specificity 89%
Sunderland et al, JAMA 2003
0
![Page 14: Dementia Update](https://reader035.fdocuments.us/reader035/viewer/2022062408/56814462550346895db0f7fb/html5/thumbnails/14.jpg)
Biomarkers: Amyloid PET
Normalcognition
Alzheimerdementia
Normalcognition
• Correlates with microscopic pathology and CSF• Detectable 10-15 years before cognitive changes• Not specific for AD—amyloid deposition occurs in Lewy
dementia, vascular dementia, NPH, probably others
![Page 15: Dementia Update](https://reader035.fdocuments.us/reader035/viewer/2022062408/56814462550346895db0f7fb/html5/thumbnails/15.jpg)
New Conceptualization
Dubois et al, Lancet Neurology 2010
Impaired memory Biomarkers Other requirements
Presymptomatic No +• AD mutation• No symptoms
Asymptomatic at risk No + No symptoms
Mild Cognitive Impairment Nonspecific biomarkers or
symptoms
![Page 16: Dementia Update](https://reader035.fdocuments.us/reader035/viewer/2022062408/56814462550346895db0f7fb/html5/thumbnails/16.jpg)
New Conceptualization
Dubois et al, Lancet Neurology 2010
Impaired memory Biomarkers Other requirements
Typical Alzheimer disease + +
Prodromal Alzheimer disease
+ +• Symptoms present• No dementia
Typical Alzheimer dementia + + Dementia
![Page 17: Dementia Update](https://reader035.fdocuments.us/reader035/viewer/2022062408/56814462550346895db0f7fb/html5/thumbnails/17.jpg)
Progress? Perhaps
Number of new Alzheimer disease medications since
2003
25,0000
Number of new Alzheimer disease publications since
2003
![Page 18: Dementia Update](https://reader035.fdocuments.us/reader035/viewer/2022062408/56814462550346895db0f7fb/html5/thumbnails/18.jpg)
Current AD Treatments
Some effect on symptoms, but…Overall effect is smallDo not stop progression of symptomsNo effect on underlying disease
Disease modification neededStop or reverse pathophysiologyPathology-related symptoms will follow
![Page 19: Dementia Update](https://reader035.fdocuments.us/reader035/viewer/2022062408/56814462550346895db0f7fb/html5/thumbnails/19.jpg)
APPAβ Peptide
p-Tau SynapticDysfunction
OxidationCell Injury
Inflammation
Cell-to-cellPropagation
Cell Death/Atrophy
Transmitter Deficits
NFT
NeuriticPlaque
Cummings, 2011
Amyloid CascadeX=failed trial
X
XX
X
XX
X
X
X
X
X
X
X
XX
X X
X
X
X
![Page 20: Dementia Update](https://reader035.fdocuments.us/reader035/viewer/2022062408/56814462550346895db0f7fb/html5/thumbnails/20.jpg)
Why Have Trials Failed?Wrong drugs?
Wrong trial subjects?Already symptomatic—too lateSome subjects probably do not have AD
No use of biomarkersMinimal autopsy follow-up
Wrong hypothesis?Amyloid pathology ≠ symptomsPhospho-tau possibly a better target
![Page 21: Dementia Update](https://reader035.fdocuments.us/reader035/viewer/2022062408/56814462550346895db0f7fb/html5/thumbnails/21.jpg)
The Future of AD TrialsTrials at earlier disease stages
Mutation carriersAmyloid PETStop disease before brain damage occurs
Increased use of biomarkersImprove subject selectionDisease-based (rather than symptom-based)
outcomes
![Page 22: Dementia Update](https://reader035.fdocuments.us/reader035/viewer/2022062408/56814462550346895db0f7fb/html5/thumbnails/22.jpg)
Non-Alzheimer Dementias
![Page 23: Dementia Update](https://reader035.fdocuments.us/reader035/viewer/2022062408/56814462550346895db0f7fb/html5/thumbnails/23.jpg)
Why Am I Bothering You?Non-AD dementias can mimic ADTreatments may differTypes of symptoms differRates of symptom development differTo make you smart and powerful
![Page 24: Dementia Update](https://reader035.fdocuments.us/reader035/viewer/2022062408/56814462550346895db0f7fb/html5/thumbnails/24.jpg)
Common Non-AD Dementias
Late onset (majority)Alzheimer disease (54%)Vascular (16%)Lewy body (16%)Other (14%)
Kester et al, Neurol in Practice. 2009; 9Schneider et al, Brain. 2012 Oct
86% of dementiaPatients 60 yo
![Page 25: Dementia Update](https://reader035.fdocuments.us/reader035/viewer/2022062408/56814462550346895db0f7fb/html5/thumbnails/25.jpg)
Common Non-AD Dementias
Young onsetAlzheimer disease (34%)Vascular (18%)FTLD (12%)Lewy body (7%)Alcohol (10%)Other (19%)
Harvey et al, J Neurol Neurosurg Psychiatr .2003; 74
81% of dementia patients < 60 yo
![Page 26: Dementia Update](https://reader035.fdocuments.us/reader035/viewer/2022062408/56814462550346895db0f7fb/html5/thumbnails/26.jpg)
Diagnostic Flow
1. Alzheimer or not?
2. Lewy or vascular?
3. FTLD?
4. Other
NOT. Step 2
NEITHER. Step 3
NOT. Reconsider1 and 2
![Page 27: Dementia Update](https://reader035.fdocuments.us/reader035/viewer/2022062408/56814462550346895db0f7fb/html5/thumbnails/27.jpg)
Diagnostic Flow
1. Alzheimer or not?
2. Lewy or vascular?
3. FTLD?
4. Other
NOT. Step 2
NEITHER. Step 3
NOT. Reconsider1 and 2
![Page 28: Dementia Update](https://reader035.fdocuments.us/reader035/viewer/2022062408/56814462550346895db0f7fb/html5/thumbnails/28.jpg)
Alzheimer vs Non-Alzheimer
COGNITION Alzheimer Non-Alzheimer
Language Often affected FTLD, Lewy
MemoryFailure to store information
Failure to spontaneously retrieve
Visuospatial Impaired Impaired
Frontal dysfunction Usually minimal early Frequently involved
Mental speed Usually normal early Often slowed
PersonalityTypically unchanged (irritability, depression)
Often apathetic, abulic
![Page 29: Dementia Update](https://reader035.fdocuments.us/reader035/viewer/2022062408/56814462550346895db0f7fb/html5/thumbnails/29.jpg)
Alzheimer vs Non-Alzheimer
MOTOR Alzheimer Non-Alzheimer
Articulation Normal Often affected
Posture Normal Often stooped or extended
Coordination Typically normal Impaired
Adventitious movements
Usually noneChorea, tremor, tics, dystonia, myoclonus
Motor speed Normal Slow
![Page 30: Dementia Update](https://reader035.fdocuments.us/reader035/viewer/2022062408/56814462550346895db0f7fb/html5/thumbnails/30.jpg)
Alzheimer vs Non-Alzheimer
Hippocampus
Entorhinal
Perirhinal
Mesial Temporal Atrophy Parieto-temporal Hypometabolism
MRI FDG-PET
![Page 31: Dementia Update](https://reader035.fdocuments.us/reader035/viewer/2022062408/56814462550346895db0f7fb/html5/thumbnails/31.jpg)
Alzheimer vs Non-Alzheimer
Other testsCSF studies
Elevated phospho-tauDecreased beta-amyloid
Amyloid imagingNegative scan incompatible with ADPositive scan compatible but not definitive
![Page 32: Dementia Update](https://reader035.fdocuments.us/reader035/viewer/2022062408/56814462550346895db0f7fb/html5/thumbnails/32.jpg)
Diagnostic Flow
1. Alzheimer or not?
2. Lewy or vascular?
3. FTLD?
4. Other
NOT. Step 2
NEITHER. Step 3
NOT. Reconsider1 and 2
![Page 33: Dementia Update](https://reader035.fdocuments.us/reader035/viewer/2022062408/56814462550346895db0f7fb/html5/thumbnails/33.jpg)
Lewy Body vs Vascular Dementia
Characteristic of both“Parkinsonism”
BradykinesiaRigidity Antipsychotic sensitivity (worse in DLB)
Early gait abnormalities and fallingDepression and/or apathy
![Page 34: Dementia Update](https://reader035.fdocuments.us/reader035/viewer/2022062408/56814462550346895db0f7fb/html5/thumbnails/34.jpg)
Lewy Body vs Vascular Dementia
More characteristic of Lewy body Visual hallucinations Episodes of decreased consciousness REM behavior disorder—synucleinopathy Marked cognitive fluctuations
More characteristic of vascular Isolated deficits (large-vessel cortical) Focal motor signs Urinary symptoms
![Page 35: Dementia Update](https://reader035.fdocuments.us/reader035/viewer/2022062408/56814462550346895db0f7fb/html5/thumbnails/35.jpg)
Lewy Body vs Vascular Dementia
Diagnostic testing MRI very sensitive for cerebrovascular disease Occipital and posterior parietal hypometabolism
on FDG PET in Lewy (sensitivity 90%, specificity 80%)
Dopamine transporter SPECT Reflects death of dopaminergic cells Abnormal in Lewy body (specificity 93.6%) Also abnormal in related disorders (PD, MSA, PSP,
CBD)
Papathanasiou et al, Parkinsonism Related Disord. 2012 Mar; 18(3)
![Page 36: Dementia Update](https://reader035.fdocuments.us/reader035/viewer/2022062408/56814462550346895db0f7fb/html5/thumbnails/36.jpg)
Diagnostic Flow
1. Alzheimer or not?
2. Lewy or vascular?
3. FTLD?
4. Other
NOT. Step 2
NEITHER. Step 3
NOT. Reconsider1 and 2
![Page 37: Dementia Update](https://reader035.fdocuments.us/reader035/viewer/2022062408/56814462550346895db0f7fb/html5/thumbnails/37.jpg)
FTLD Subtypes
Behavioral Personality change Dec social awareness Ritualistic and rigid Emotional blunting Lack of insight
![Page 38: Dementia Update](https://reader035.fdocuments.us/reader035/viewer/2022062408/56814462550346895db0f7fb/html5/thumbnails/38.jpg)
Progressive nonfluent aphasia Starts with anomia (word-finding, naming) Circumlocution Phonemic (sound) paraphasias Agrammatism Usually retained insight L>R frontal >temporal atrophy
FTLD Subtypes
Snowden et al, Brain. 2006; 129
![Page 39: Dementia Update](https://reader035.fdocuments.us/reader035/viewer/2022062408/56814462550346895db0f7fb/html5/thumbnails/39.jpg)
FTLD Subtypes
Semantic dementia Impaired comprehension Normal fluency Semantic (concept)
paraphasias Normal repetition Usually little insight L>R temporal atrophy
Boeve et al, Neurology. 2001; Oct 23
![Page 40: Dementia Update](https://reader035.fdocuments.us/reader035/viewer/2022062408/56814462550346895db0f7fb/html5/thumbnails/40.jpg)
Summary Alzheimer disease is the most common
cause of dementia Alzheimer, vascular, Lewy, and FTLD
account for >80% of dementias There are distinguishing in vivo
characteristics of these diseases Most cases of dementia can be diagnosed
with confidence (i.e., neurologists aren’t that smart)
![Page 41: Dementia Update](https://reader035.fdocuments.us/reader035/viewer/2022062408/56814462550346895db0f7fb/html5/thumbnails/41.jpg)